Cite
HARVARD Citation
Goldberg, S. et al. (n.d.). Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. Lancet oncology. 17 (7), pp. 976-983. [Online].